The development of plasma-derived hepatitis B virus (HBV) vaccines, succeeded by safe and efficacious recombinant HBsAg vaccines 1, has opened the way to mass vaccination against hepatitis B. Most candidates for hepatitis B vaccination are either infants or young adults. However, hepatitis B vaccination is also indicated for elderly subjects in high-risk groups. Among the risk factors are admission to chronic care facilities, chronic haemodialysis and visits to endemic areas. Some elderly health care workers also require hepatitis B vaccination. There are suggestions but no definite proof that the response to vaccination declines with advancing age, as has been described for the influenza virus 2. A negative effect of age on the response to hepatitis B vaccination in healthy volunteers 3"4, patients with Down's syndrome 5 and patients on chronic haemodialysis 6'~ has been reported. Plasma-derived vaccines were used in these studies. It is not clear whether there are other negative influences or whether the possible negative effect of age can be overcome, for instance by the use of recombinant HBsAg vaccine or by increasing the dose of hepatitis B vaccine. We therefore compared the effect of 10 #g and 20 #g yeast-derived recombinant HBsAg in a standard schedule with vaccinations at 0, 1 and 6 months in 112 healthy elderly volunteers. The dose of 20#g is recommended and is probably above optimal in healthy adolescents 1. A dose of 10/zg was used for comparison because the effect of other factors, such as age and general health, were expected to be more readily discernible at this dose.
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PATIENTS AND METHODS
A total of 116 healthy volunteers aged 59 years and older were screened for inclusion in the study. Healthy was defined as being self-supporting and free of lifethreatening disease. The number of men was 65. (Table 1 ).
The study was approved by the ethical committees of the participating centres. Of the 116 volunteers screened, three men and one woman were anti-HBs-and anti-HBc-positive, and these four were excluded. The remaining 112 volunteers were included in the study. Participants were randomized by order of entry in fixed blocks of six. A vaccine dose of 10pg (scheme A) yeast-derived recombinant HBsAg (Engerix-B) was given to 56 subjects and a dose of 20 pg (scheme B) was given to the remaining 56 by intramuscular injection in the deltoid region. There were no significant differences between groups with regard to age, sex, setting, daily amount of alcohol consumed or number of current prescriptions. Injections were given at 0, 1 and 6 months. Blood was drawn from an antecubital vein for anti-HBs measurement by radioimmunoassay (Ausab, Abbott Laboratories, Chicago, IL, USA; using a WHO standard) at 2, 6 and 7 months. Five persons withdrew before completion of the study, three in scheme A and two in scheme B, one because of a rise in his insulin requirement and the others for non-medical reasons. No other side-effects of vaccination were noted. Three anti-HBs titres at 2 months are missing in the remaining 107 patients, two in scheme A and one in scheme B. By interpolation, the two missing values in scheme A can be assumed to equal zero. No anti-HBs titre at 7 months is available for one patient in scheme A. In the statistical analysis, actuarial (Kaplan-Meier) response rates for the total group of 112 participants and absolute response rates for the 106 subjects who had anti-HBs measured at 7 months were almost identical. In this report, only absolute numbers will be considered. Non-parametric tests (Fisher and Mann-Whitney) were used for the comparison of groups. Logistic regression analysis was used for multivariate testing of the effects on response rate. In a study of 112 patients at ~=0.05 and fl=0.10, differences of <30% between two groups may go undetected.
RESULTS
An anti-HBs titre ~> 10 IU 1-1 at 7 months was found in 30 out of 52 subjects in scheme A (58%, 95% confidence interval (CI): 45-71%) and in 34 out of 54 in scheme B (63%, 95% CI: 50-76%). At two months, these figures were 12 and 9%, respectively, and at 6 months they were 27 and 24%, respectively (Figure 1 ). Immunogenicity of rHBsAg vaccine in elderly subjects: S. de Rave et al. the first vaccination is the only independent factor related to presence or absence of an anti-HBs response ~> 10 IU 1-1 after 7 months (p =0.001).
DISCUSSION
The present study clearly shows that the response rate in elderly volunteers vaccinated with yeast-derived rHBsAg (60%, 95% CI: 51-70%) was below that expected for healthy adolescents. For 870 healthy volunteers below the age of 40 years, a response rate of 99.5% (95% CI: 99.1-100%) has been reported after a vaccination course identical to that in our study 1. In a study in 141 newborns 8 conducted at the same time with the same vaccine, a 100% response to vaccination was found, which makes technical flaws related to the vaccine or to the antibody measurements an unlikely reason for our finding of low responsiveness. Contrary to our expectations, we found no differences between the 10/~g and the 20 #g doses. The only factor with a negative influence on the response rate in our study was the use of medication at the time of the first vaccination. The response rate was 78% (95% CI: 6689%) in the group without medication compared with 46% (95% CI: 33-59%) in the group using one or more prescriptions. The use of medication may reflect poorer general health in the latter group. Even in the subjects without medication, the response rate was below that reported for younger age groups. Within the group studied here, we found no relationship between age and response to vaccination, contrary to the report by Denis et al. 3 . Their study does not mention the use of medication by the vaccinees, which may be an alternative explanation for the difference found between their age categories.
In conclusion, age appears to be a very important factor in the immune response to recombinant HBsAg, even though our study did not include a younger control group. Within the group of elderly volunteers, the response to vaccination with yeast-derived recombinant HBsAg is further influenced by general health as reflected by the use of medication.
